KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

CRISPR Therapeutics AG (CRSP) Net Margin (2016 - 2025)

Historic Net Margin for CRISPR Therapeutics AG (CRSP) over the last 10 years, with Q4 2025 value amounting to 18881.94%.

  • CRISPR Therapeutics AG's Net Margin fell 186605600.0% to 18881.94% in Q4 2025 from the same period last year, while for Dec 2025 it was 17496.7%, marking a year-over-year decrease of 164032900.0%. This contributed to the annual value of 17496.47% for FY2025, which is 164031300.0% down from last year.
  • According to the latest figures from Q4 2025, CRISPR Therapeutics AG's Net Margin is 18881.94%, which was down 186605600.0% from 11973.12% recorded in Q3 2025.
  • In the past 5 years, CRISPR Therapeutics AG's Net Margin ranged from a high of 84.29% in Q2 2021 and a low of 1880950.0% during Q4 2022
  • Its 5-year average for Net Margin is 124890.38%, with a median of 15722.08% in 2025.
  • Its Net Margin has fluctuated over the past 5 years, first tumbled by 2000000000bps in 2022, then soared by 2000000000bps in 2023.
  • Over the past 5 years, CRISPR Therapeutics AG's Net Margin (Quarter) stood at 1095.03% in 2021, then crashed by -171671bps to 1880950.0% in 2022, then skyrocketed by 100bps to 29.13% in 2023, then crashed by -860bps to 221.38% in 2024, then plummeted by -8429bps to 18881.94% in 2025.
  • Its Net Margin was 18881.94% in Q4 2025, compared to 11973.12% in Q3 2025 and 23380.83% in Q2 2025.